Drug Trial Radar · NCT06775405
A Study to Confirm the Effectiveness and Safety of AK0529 in Treating RSV Infections in Hospitalized Infants
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Feb 29, 2024
Primary completion
Apr 7, 2025
Study completion Apr 16, 2025
Sponsor
- Lead sponsor
- Shanghai Ark Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 1 month, up to 24 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Respiratory syncytial virus (RSV) is the most common respiratory infectious pathogen recognized worldwide that poses serious health risks to infants, and an important cause of hospitalization for severe respiratory infections in infants. Serious respiratory problems such as pneumonia caused by RSV are one of the leading causes of death from respiratory diseases in infants. AK0529 targets the Pre-F (fusion) protein on the surface of the viral envelope. Specifically, it prevents the virus from invading uninfected cells and inhibits the fusion between host cells by inhibiting the fusion of the F (fusion) proteins on the surface of the RSV envelope, thus providing the effects of anti-RSV infection. This is a randomized, double-blind, placebo-controlled, multicenter, phase III clinical study to evaluate the efficacy and safety of AK0529 in hospitalized infants aged 1 to 24 months with RSV infection. Considering the benefits of AK0529 in the population with RSV infection, hospitalized infants with moderate to severe RSV infection were selected as the target population for this study.
Conditions
- Respiratory Synctial Virus Infections
Interventions
AK0529Drug
Active Substance: AK0529, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
PlaceboDrug
Active Substance: Placebo, Pharmaceutical Form: Enteric pellets, Route of Administration: Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the Wang bronchiolitis clinical scoreTime frame: Day 3 (48 hours)
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Beijing Children's Hospital, Capital Medical University
Beijing, China
First Hospital of Jilin University
Changchun, China
Hunan Provincial People's Hospital
Changsha, China
West China Second University Hospital, Sichuan University
Chengdu, China
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, China
Sanya Central Hospital, Hainan Third People's Hospital
Sanya, China
Shanghai Children's Hospital, Shanghai Jiao Tong University
Shanghai, China
Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Shengjing Hospital of China Medical University
Shenyang, China
Tianjin Children's Hospital(Longyan)
Tianjin, China
Tianjin Children's Hospital(Machang)
Tianjin, China
Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
Wenzhou, China
Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China
Wuxi Children's Hospital
Wuxi, China
First Affiliated Hospital of Xiamen University
Xiamen, China
Women and Children's Hospital, and the School of Medicine, Xiamen University
Xiamen, China
Zhongshan Women and Children's Hospital-Zhongshan Boai Hospital
Zhongshan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.